Subscribe to RSS
Download PDF
DOI: 10.1160/TH02-09-0061
Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis
Financial support: The study was supported by Novartis Pharma GmbH, Nuremberg, Germany. The results of the study were presented in part at the 42nd Annual Meeting of the American Society of Hematology, San Francisco, CA, December 04, 2000 and the XVIIIth Congress of the International Society on Thrombosis and Haemostasis, Paris, France, July 10, 2001.
Publication History
Received
12 September 2003
Accepted after revision
12 May 2003
Publication Date:
06 December 2017 (online)
Summary
Subcutaneous body weight-adjusted low molecular weight heparin (LMWH) has been proven as effective and safe as intravenous aPTT-adjusted unfractionated heparin (UFH) for the treatment of patients with acute deep venous thrombosis (DVT). In this study we evaluate the efficacy of the initial treatment of proximal DVT with a fixed-dose, body weight-independent application of the LMWH Certoparin with a six month follow-up.
In a prospective, multicentre, randomized, active-controlled study 1220 patients with objectively diagnosed proximal DVT were randomly assigned to subcutaneous 8000 U anti-factor Xa of Certoparin twice daily for 10 to 14 days or intravenous aPTT-adjusted UFH for 5 to 8 days. Both regimen were followed by oral anticoagulation for 6 months. The primary end point was the rate of symptomatic and objectively confirmed thromboembolic events within 6 months. The aim of the study was to demonstrate the non-inferiority of the Certoparin regimen as compared to UFH.
The per-protocol analysis revealed 22 (3.8%) thromboembolic events in the Certoparin group and 24 (4.3%) in patients assigned to UFH within 6 months, thereby proving the non-inferiority (p<0.01), confirmed by intent-to-treat analysis (p<0.001). Major bleeding occurred in 6 and 7 patients started on Certoparin or UFH during the treatment period. Thromboembolic events were equally distributed in body weight categories with < 50,50-80 and >80 kg as followed:0,3.6% and 4.1% of patients for the Certoparin group and 0, 4.6% and 4.2% of patients for the UFH group. The same was true for major bleeding complications with 0, 2.9% and 1.5% for Certoparin and 0, 3.5% and 4.2% for UFH. Overall mortality was 1.9 % in the Certoparin group and 2.7 % in the UFH group.
Fixed-dose body weight-independent subcutaneous LMWH Certoparin is at least as efficacious and safe as intravenous aPTT-adjusted UFH for the initial treatment of acute proximal DVT. This effect is maintained during a 6-months follow-up of treatment with oral anticoagulation.
-
References
- 1 Hull RD, Pineo GF. Low-molecular-weight heparin in the treatment of venous thromboembolism. Sem Thromb Hemost 2000; 26 (Suppl. 01) Suppl 61-7.
- 2 Hull RD, Raskob GE, Brant RF. et al. Low-molecular-weight heparin vs. heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000; 160: 229-36.
- 3 Merli GJ. Low-molecular-weight heparins versus unfractionated heparin in the treatment of deep vein thrombosis and pulmonary embolism. Am J Phys Med Rehabil 2000; 79 Suppl S9-S16.
- 4 Davidson BL. Differentiation of low molecular weight heparins in treatment of acute deep vein thrombosis. Sem Thromb Hemost 1999; 25 (Suppl. 03) Suppl 107-12.
- 5 Kirchmaier CM, Wolf H, Schäfer H, Ehlers B, Breddin HK. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Int Angiol 1998; 17: 135-45.
- 6 Harenberg J, Schmidt JA, Koppenhagen K, Tolle A. Huisman MV and the EASTERN Investigators. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. Thromb Haemost 2000; 83: 652-6.
- 7 Harenberg J, Huisman MV, Tolle AR, Breddin HK, Kirchmaier CM. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with fixed-dose body weight-independent low-molecular-weight heparin certoparin. Semin Thromb Hemost 2001; 27: 513-8.
- 8 Bauer P, Köhne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50: 1029-41.
- 9 Blackwelder WC. Proving the null hypothesis in clinical trials. Control Clin Trials 1982; 3: 345-53.
- 10 Jennison C, Turnbull BW. Repeated confidence intervals for group sequential clinical trials. Control Clin Trials 1984; 5: 33-45.
- 11 Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol 1998; 82: 3L-10L.
- 12 Van der Heijden JF, Prins MH, Büller HR. For the initial treatment of venous thromboembolism: Are all low-molecular-weight heparin compounds the same?. Thromb Res 2000; 100: V121-V30.
- 13 Boneu B. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis. Thromb Res 2000; 100: 113-20.
- 14 Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. Arch Intern Med 2000; 160: 181-8.
- 15 Rocha E, Martinez-Gonzalez MA, Montes R, Panizo C. Do the low molecular weight heparins improve efficacy and safety of the treatment of deep venous thrombosis? A meta-analysis. Haematologica 2000; 85: 935-42.
- 16 Van den Belt AGM, Prins MH, Lensing AWA. et al. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Library Syst Rev 2000; 1: 1-18.
- 17 Breddin HK, Hach-Wunderle V, Nakov R, Kakkar VV. for the CORTES Investigators. Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 2001; 344: 626-31.
- 18 Anand SS, Bates S, Ginsberg JS. et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999; 159: 2029-32.
- 19 Bacher P, Welzel D, Iqbal O. et al. The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model. Thromb Res 1992; 66: 151-8.
- 20 Kirchmaier CM, Lindhoff-Last E, Rübesam D. et al. Regression of deep vein thrombosis by i.v.-administration of a low molecular weight heparin. Results of a pilot study. Thromb Res 1994; 73: 337-48.
- 21 Fiessinger JN, Lopez-Fernandez M, Gatterer E. et al. Once-daily subcutaneous Dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996; 76: 195-9.
- 22 Charbonnier BA, Fiessinger J-N, Banga JD, Wenzel E, d´Azemar P, Sagnard L. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. Thromb Haemost 1998; 79: 897-901.
- 23 Merli G, Spiro TE, Olsson C-G. et al. Subcutaneous enoxaparin once or twice daily com-pared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001; 134: 191-202.
- 24 Couturaud F, Julian JA, Kearon C. Low molecular weight heparin administered once ver-us twice daily in patients with venous thromboembolism. A meta-analysis. Thromb Haemost 2001; 86: 980-4.